Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The next generation of immunotherapy: keeping lung cancer in check
Published: 24 April 2017
Durvalumab is being evaluated in combination with bavituximab in pretreated, advanced NSCLC patients. Bavituximab is an inhibitor of phosphatidylserine which is an immunosuppressive molecule expressed on tumor cells and exosomes in the tumor microenvironment. Bavituximab has shown improvement in median OS in nonsquamous, pretreated, advanced NSCLC patients with combination with docetaxel over control (11.7 versus 7.3 months). Early phase trials will evaluate bavituximab in combination with durvalumab until progression or toxicity, with a primary endpoint of ORR, and secondary endpoints of PFS, OS, and safety [54].
http://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0456-5
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Nature Reviews Cancer 17, 286–301 (2017) doi:10.1038/nrc.2017.17 Published online 24 March 2017
Anti-Phosphatidylserine Antibody, clone 1H6
https://www.emdmillipore.com/CA/en/product/Anti-Phosphatidylserine-Antibody%2C-clone-1H6,MM_NF-05-719#overview
Dendritic cells expressing immunoreceptor CD300f are critical for controlling chronic gut inflammation
https://www.jci.org/articles/view/89531
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
http://jem.rupress.org/content/214/4/895
PS and mother milk again:
https://m.medicalxpress.com/news/2017-04-breast-weapon-cancer.html
For my German speaking friends:
http://mobil.derstandard.at/2000055664195/Mit-Muttermilch-gegen-Krebszellen
Originalpublikationen:
http://www.sciencedirect.com/science/article/pii/S0005273615002400
Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine
http://link.springer.com/article/10.1007%2Fs10534-014-9749-0
Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine
http://www.sciencedirect.com/science/article/pii/S0005273611002318
In search of a novel target — Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy
May be they have put a "," into the text somewere.
Last updated 18. April 2017 Gemcitabine / Bavituximab
https://clinicaltrials.gov/ct2/show/NCT01272791?term=Pancreatic+Cancer&lup_s=03%2F23%2F2017&lup_d=30
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Bavituximab in there.
https://www.google.at/url?sa=t&source=web&rct=j&url=http://journals.sagepub.com/doi/pdf/10.1177/1010428317691001&ved=0ahUKEwiLuIXe0LfTAhXBVSwKHf1kDJo4HhAWCCAwAg&usg=AFQjCNGj0rg5oWdFiOgpccITKZN2xp3sMA
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells
Summary
We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine - a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine-high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine-targeting small molecules for the treatment of surface phosphatidylserine-expressing cancers.
Updated Landscape of the Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine
RESEARCH-ARTICLE
Yu Sun1, 2, 3* and Paul Chiao1, 4
[1] Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiaotong University School of Medicine, Shanghai, China
[2] Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiaotong University School of Medicine, Shanghai, China
[3] Department of Medicine and VAPSHCS, University of Washington, Seattle, WA, USA
[4] Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract
Despite successive advances in clinical diagnosis and therapeutic intervention, cancer-associated morbidity and mortality keeps up with escalating cost to human society. Clinicians are confronted with an unprecedented challenge in curing cancers with de novo or acquired resistance. Failure to achieve effective and long-lasting treatment effects arises from the complexity of malignancies, particularly when plasticity of cancer cells is coupled with survival adaptability conferred by the pathologically co-opted stroma in the tumor microenvironment (TME). Targeting immune checkpoints, such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA4), provide significant benefit in multiple tumor types and produce substantial anticancer responses. Tissue resident stromal cells, although damaged together with cancer cells upon cytotoxic treatments, represent an ever-replenishing source that contributes to tumor restoration from residual cancer cells in the post-therapy stage. The TME displays a continually changing landscape, generating significant impacts on treatment outcome in clinics. Moving forward, implementing patient-specific analysis in clinical oncology with TME-oriented agents will significantly improve the specificity and efficacy of targeted therapies, thereby accelerating the translation of novel conceptions and groundbreaking discoveries in the TME biology through multiple bench-to-bed pipelines in current settings of precision cancer medicine.
https://www.intechopen.com/books/patient-centered-medicine/updated-landscape-of-the-tumor-microenvironment-and-targeting-strategies-in-an-era-of-precision-medi#article-front
Reversing T-cell Dysfunction and Exhaustion in Cancer
ANALYSIS-As AstraZeneca chases rivals, immuno-oncology gets complicated - RTRS
19-Apr-2017 16:47
AZ lung cancer combination drug trial data due mid-year
Merck, Bristol, Roche also have important upcoming news
Competition for $20 bln first-line lung cancer market
By Ben Hirschler
LONDON, April 19 (Reuters) - Three years after Pfizer's PFE.N failed bid for AstraZeneca AZN.L, the British drugmaker aims to prove in the coming weeks that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle.
Central to AstraZeneca's case is a trial called MYSTIC which is testing the drugs durvalumab and tremelimumab in lung cancer. If initial results to be reported at mid-year indicate success, this could confirm the company's place at oncology's top table.
But the market for medicines boosting the immune system's ability to fight tumours is increasingly competitive and the science is moving fast, raising questions as to whether AstraZeneca can produce a knock-out win.
Merck & Co MRK.N, Bristol-Myers Squibb BMY.N and Roche ROG.S already have similar drugs approved in lung cancer and the race is on to launch effective combinations for previously untreated disease in patients - a potentially huge market.
"I think there will be multiple approvals in the first-line (untreated) space," Naiyer Rizvi, head of thoracic oncology at Columbia University Medical Center, told Reuters. "The question is going to be how do you position all these different options."
Durvalumab and tremelimumab are immuno-oncology (I-O) drugs which, by helping the body's immune cells kill cancer, offer an alternative to toxic chemotherapy. While not without side effects, I-O is a kinder option that also promises longer-lasting efficacy, although the high cost is a concern. (Full Story)
Analysts at Jefferies see a $20 billion opportunity for I-O drugs in first-line non-small cell lung cancer, with sales split between I-O monotherapy (administering one such medicine on its own); I-O plus conventional chemotherapy; and combinations of two I-O drugs, as in AstraZeneca's approach.
"There's a critical unmet need, which is why there is so much excitement about immunotherapies and so much activity," said Rob Iannone, AstraZeneca's head of late-stage I-O development. "Current outcomes are still very, very poor."
As experience builds with using the new agents, rival drugmakers have been busily amending clinical trial plans to keep up with a shifting landscape, while also launching new studies to exploit a coming second generation of I-O medicines.
The issue has been further complicated by doubts over how to identify patients who will benefit. The latest data suggests that the level of mutation in tumours may be a better biomarker than the current widely used benchmark, a protein called PDL-1.
"PDL-1 is a bit of a blunt instrument," said Rizvi. "In future, I think you will see a lot better science around identifying patients based on their genetics."
BIG SHARE PRICE SWING
AstraZeneca shares, which at around 46 pounds still trail the 55 pounds offered by Pfizer in 2014, are expected to move sharply up or down on the MYSTIC data.
But the result may not be as clear-cut as some investors hope because the full data will emerge in stages.
Headline news on progression-free survival (PFS), or extending the time before cancer worsens, is due in June or July, with details following later, possibly at the European Society for Medical Oncology congress in Madrid in September.
Doctors, patients and investors may have to wait until 2018 to learn whether durvalumab and tremelimumab actually help patients live longer by extending overall survival (OS).
Given the competitive landscape, the pressure is on to achieve both PFS and OS. "In the first-line setting, I think it is important to hit both," said Rizvi, who is principal investigator for the MYSTIC trial.
Indeed, a miss on PFS could be enough to mark AstraZeneca as a likely loser in the multibillion-dollar I-O race, according to UBS analysts.
AstraZeneca's Iannone sees it rather differently, arguing that the durable response generated by I-O drugs makes long-term survival, not PFS, the gold standard test.
"It looks as if OS is a more robust endpoint," he said. "We want to preserve PFS, even if we know that the study might ultimately have to wait for OS to appreciate the full benefit."
Importantly, AstraZeneca has built multiple options into its trial design, with potential to prove that durva/treme can help all patients or a subset with high levels of PDL-1. In addition, durvalumab is being tested on its own.
Back in 2014, AstraZeneca predicted durvalumab could have peak sales of $6.5 billion, including combination therapies, making it the biggest contributor to revenue growth.
Current analyst forecasts are only around half this level, according to Thomson Reuters data, making the next few weeks pivotal in building or eroding expectations.
AstraZeneca has two chances to build confidence ahead of MYSTIC, with durvalumab potentially winning approval in bladder cancer - a relatively small market - and data also due from a lower-profile lung cancer trial called ARCTIC.
But rivals are moving fast. Merck is expected to get a U.S. green light to sell a combination of its I-O drug Keytruda and chemotherapy in first-line lung cancer by May 10, while Bristol-Myers and Roche also have important upcoming combination data.
All of this makes success critical for AstraZeneca, which is struggling with falling sales from loss of patents on blockbusters such as cholesterol drug Crestor and is doing external deals to help fund new-drug research.
Pfizer may have left the stage but some analysts and bankers believe AstraZeneca could become a target again in any future wave of pharmaceutical industry consolidation. (Full Story)
(editing by David Stamp)
((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net))
Quest Diagnostics with Phosphatidylserine Test
Phosphatidylserine Antibodies (IgG, IgA, IgM)
Test Code
http://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=10062&labCode=SKB
So Reuters must be wrong then!
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Peregrine Pharmaceuticals, Inc.
(Name of Issuer)
Series E Preferred Stock
(Title of Class of Securities)
713661403
(CUSIP Number)
John S. Stafford, III
c/o Ronin Capital, LLC
350 N. Orleans Street, Suite 2N
Chicago, IL 60654
(312) 244-5284
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
April 6, 2017
Ronin Capital, LLC
· On February 27, 2017, Ronin Capital, LLC purchased 35,152 shares at a price of $20.14790 per share.
· On February 28, 2017, Ronin Capital, LLC purchased 6,482 shares at a price of $20.30180 per share.
page 9
------------------------------------------------------------------
· On March 1, 2017, Ronin Capital, LLC purchased 4,430 shares at a price of $20.60290 per share.
· On March 2, 2017, Ronin Capital, LLC purchased 14,667 shares at a price of $21.65650 per share.
· On March 3, 2017, Ronin Capital, LLC purchased 11,040 shares at a price of $22.12210 per share.
· On March 6, 2017, Ronin Capital, LLC sold 46 shares at a price of $22.35 per share.
· On March 28, 2017, Ronin Capital, LLC purchased 1,807 shares at a price of $21.60 per share.
· On April 6, 2017, Ronin Capital, LLC purchased 5,817 shares at a price of $22.15820 per share.
· On April 7, 2017, Ronin Capital, LLC purchased 10,510 shares at a price of $22.055 per share.
· On April 10, 2017, Ronin Capital, LLC purchased 5,200 shares at a price of $21.96154 per share.
SW Investment Management LLC
· On January 24, 2017, SW Investment Management LLC purchased 1,273 shares at an average price of $20.3841 per share.
· On February 23, 2017, SW Investment Management LLC purchased 27 shares at an average price of $19.80 per share.
SWIM Partners LP
· On January 24, 2017, SWIM Partners LP purchased 3,820 shares at an average price of $20.384135 per share.
· On February 23, 2017, SWIM Partners LP purchased 180 shares at an average price of $19.80 per share.
I hope so....
-53,84% must be 53,84% of their portofolio
It´s from Reuters.
Did Ronin sold ALL PPHM????
Holding Name Latest Filing Date % Portfolio Position Change
Aware Inc 14-01-2017 84,02% 3,25M +0,01M
Kingstone Companies 12-08-2016 14,53% 0,39M -0,08M
Top Ships Inc TOPS.OQ 31-08-2016 1,46% 0,09M +0,08M
Peregrine Pharmaceuticals 17-04-2017 -23,67M
Recent Activity Recent Activity Recent Activity Recent Activity
Increases Increases Chg % Shares
Top Ships Inc Top Ships Inc +1,24% +0,08M
Aware Inc Aware Inc +0,13% +0,01M
Decreases Decreases Chg % Shares
Peregrine Pharmaceuticals Inc Peregrine Pharmaceuticals Inc -53,84% -23,67M
Kingstone Companies Inc Kingstone Companies Inc -3,18% -0,08M
RONIN CAPITAL LLC REPORTS 5.8 PCT STAKE IN PEREGRINE PHARMACEUTICALS
RINB
17/04/2017 8:40 PM
April 17 (Reuters) - Peregrine Pharmaceuticals Inc PPHM.O: *Ronin Capital LLC reports 5.8 percent stake in Peregrine Pharmaceuticals Inc as of April 6 - sec filing
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com)) Source Date/Time = 17-APR-201718:30:43 GMT
nRSD5zs2Jb
© Thomson Reuters 2017. All rights reserved.
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells
Article in British Journal of Haematology · February 2017 with 38 Reads
DOI: 10.1111/bjh.14561
1st Slavica Vuckovic
2nd Kate Vandyke
28.09 · University of Adelaide and SA Pathology
+ 11
3rd David A. Rickards
Last Andrew T. Hutchinson
Show more authors
Abstract
We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine - a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine-high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine-targeting small molecules for the treatment of surface phosphatidylserine-expressing cancers.
https://www.researchgate.net/publication/313821981_The_cationic_small_molecule_GW4869_is_cytotoxic_to_high_phosphatidylserine-expressing_myeloma_cells
Antibody drug conjugates current status and future perspectives - SlideShare
https://www.google.at/url?sa=t&source=web&rct=j&url=https://www.slideshare.net/pranavsopory/antibody-drug-conjugates-current-status-and-future-perspectives-75089282&ved=0ahUKEwjHkJ3PgKzTAhWnBsAKHVsODiAQFggaMAA&usg=AFQjCNFNCwQ7c8KDkQ8-QuLOkPXwZWBKLg
Bavituximab slide 7
WOW 0,555 vol 1,4 Mio down 10% - some News coming?
Vol over 1 Mio - stock down 7%
I´m also following ImmunoVaccine:
HALIFAX, NOVA SCOTIA--(Marketwired - April 11, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that University Health Network's Princess Margaret Cancer Centre (http://www.uhn.ca/PrincessMargaret) (PM) has received Health Canada clearance to initiate a clinical study evaluating immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada). The Phase 2 triple-combination therapy trial is designed to evaluate the potential anti-tumor activity of Merck's pembrolizumab with Immunovaccine's lead cancer vaccine candidate, DPX-Survivac, in patients with recurrent, platinum-resistant ovarian cancer. Patients will also receive low-dose cyclophosphamide.
"There continues to be a significant unmet medical need for many ovarian cancer patients and we are pleased to have Health Canada grant clearance for this triple-combination therapy trial, which may be a means to address the complexities of the disease," said Frederic Ors, Immunovaccine's Chief Executive Officer (https://www.imvaccine.com/team_management.php...). "Research has shown that ovarian cancer can be positively impacted by the activation of T cells - the hallmark of our DPX-Survivac mechanism of action. We believe that DPX-Survivac is uniquely positioned to be the enabling agent of choice, with a novel, clinically demonstrated ability to generate relevant, sustained immune responses. The initiation of this trial will mark the next stage of development for an exciting triple-combination therapeutic approach."
Merck is funding and contributing materials for the non-randomized, open-label trial, which is expected to enroll 42 subjects with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Immunovaccine is contributing its product candidate as well as a related portion of analytical assays. The study's primary objective is to assess overall response rate (ORR). Secondary study objectives include progression free survival (PFS) rate, overall survival (OS) rate, and potential side effects, over a five-year period.
DPX-Survivac is Immunovaccine's lead immuno-oncology candidate, generated by its novel proprietary DepoVax™ adjuvanting technology platform. The DPX-Survivac target, survivin, is present in more than 20 types of solid tumor and hematologic cancers. It is involved in multiple critical pathways of cancer cell growth and survival. Prior results from a Phase 1/1b (https://www.imvaccine.com/releases.php...) study indicated that DPX-Survivac combined with a low dose of cyclophosphamide was highly immunogenic in individuals with high-risk ovarian cancer, inducing survivin- specific T cell immune responses in most trial participants.
About DPX-Survivac
DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. The National Cancer Institute (NCI) has recognized survivin as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in a higher percentage of tumors than other TAAs.
The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides. This targeted therapy attempts to use the immune system to search actively and specifically for tumor cells and destroy them. Survivin-specific T-cells have been shown to target and kill survivin-expressing cancer cells while sparing normal cells.
DPX-Survivac received Fast Track designation by the FDA as maintenance therapy in individuals with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. The FDA also granted orphan drug status to DPX-Survivac for the treatment of ovarian cancer. This designation is valid for all applications of DPX-Survivac in ovarian cancer without restriction to a specific stage of disease.
About the Princess Margaret Cancer Centre of the Toronto Hospital
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to www.theprincessmargaret.ca or www.uhn.ca.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
MEDIA
Mike Beyer
Sam Brown Inc.
T: (312) 961-2502
E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé
Chief Financial Officer
T: (902) 492-1819
E: info@imvaccine.com
Patti Bank
Managing Director
Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572
E: patti.bank@westwicke.com
© 2017 Nasdaq, Inc. All rights reserved.
Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies
Autoimmunity Highlights, Apr 2017
http://paperity.org/p/79628042/exploring-the-plasmatic-platelet-activating-factor-acetylhydrolase-activity-in-patients
it`s Friday here in Europe going home soon
Axonal Degeneration in Retinal Ganglion Cells Is Associated with a Membrane Polarity-Sensitive Redox Process
Mohammadali Almasieh, Maria-Magdalena Catrinescu, Loïc Binan, Santiago Costantino, and Leonard A. Levin
Journal of Neuroscience 5 April 2017, 37 (14) 3824-3839; DOI: https://doi.org/10.1523/JNEUROSCI.3882-16.2017
Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Published April 2017
Bingbing Dai, David Roife, Ya'an Kang, Joy Gumin, Mayrim V. Rios Perez, Xinqun Li, Michael Pratt, Rolf A. Brekken, Juan Fueyo-Margareto, Frederick F. Lang, and Jason B. Fleming
PM .6986 vol. 1200
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference - MKW
07-Apr-2017 13:05
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
HALIFAX, NOVA SCOTIA--(Marketwired - April 7, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors (https://www.imvaccine.com/team_management.php...) will present an update on the Company's recent progress and future strategy at the Bloom Burton & Co. Healthcare Investor Conference 2017 (https://www.bloomburton.com/conference/) in Toronto, Canada.
Details of the presentation are as follows:
Date: Monday, May 1, 2017
Time: 11:00 am ET
Location: Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel, Toronto, Canada
About the Conference
Bloom Burton & Co. (https://www.bloomburton.com/) is hosting its sixth annual Healthcare Investor Conference on May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada. The Company aims to showcase approximately 60 of the premier Canadian healthcare companies to its network of investors, who generally come from across Canada, the U.S. and Europe. The conference includes networking sessions, keynote speeches and panel discussions with venture capital, public equity and strategic investors. The event attracts investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies and participate in the 1-on-1 meeting system with company management.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. An investigator-sponsored Phase 2 study is currently assessing the safety and efficacy of DPX-Survivac combined with an approved anti-PD-1 drug in advanced ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com.
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502
mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbe, Chief Financial Officer T: (902) 492-1819
info@imvaccine.com
Patti Bank, Managing Director, Westwicke Partners O: (415) 513-1284
T: (415) 515-4572
patti.bank@westwicke.com
© 2017 Nasdaq, Inc. All rights reserved.
After all that news we are still under .70
Why?
Please don't answer!
Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax™-based Cancer Immunotherapy
https://www.imvaccine.com/releases.php?releases_id=421
AND
https://www.imvaccine.com/userfiles/IMMUNOVACCINE%20AACR%20Poster%202017MAR14%20GW(2).pdf
Latest Reuters news:
IMV ImmunoVaccine data show antibodies enhance DepoVax IMV.TO - Canada Stockwatch
05-Apr-2017 14:40:24
ImmunoVaccine Inc (TSX:IMV)
Shares Issued 118,954,409
Last Close 4/4/2017 $1.15
Wednesday April 05 2017 - News Release
Mr. Mike Beyer reports
IMMUNOVACCINE INC. PRESENTS PRECLINICAL RESEARCH AT AACR 2017 ON ABILITY OF NOVEL MONOCLONAL ANTIBODIES TO BOOST EFFICACY OF DEPOVAX-BASED CANCER IMMUNOTHERAPY
ImmunoVaccine Inc.'s new preclinical data presented at the 2017 American Association for Cancer Research (AACR) annual meeting has demonstrated that phosphatidylserine (PS) targeting antibodies can enhance the anti-cancer activity of its DepoVax-based therapeutic vaccine platform.
In the study, researchers combined a Peregrine Pharmaceuticals' PS-targeting antibody compound (mch1N11) with a DepoVax(TM)-based HPV16 peptide vaccine and metronomic cyclophosphamide (mCPA). This combined immunotherapy prolonged survival in C3 mouse models as compared to mice receiving an isotope control in combination with DepoVax(TM)/mCPA. Additional analysis also demonstrated an increase in T cells in the tumor following treatment. Taken together, researchers believe that the data suggests that the antibody targeting PS can increase the anti-tumor immune response induced by a DepoVax(TM)-based cancer immunotherapy.
"This study is another step in our exploration of combining DepoVax(TM)-based cancer vaccines and other promising immuno-modulatory compounds," said Marianne Stanford, PhD Vice President, Research for ImmunoVaccine. "Our process of generating supportive preclinical data to guide a potential clinical path forward has been effective in identifying these novel combinations in the past. We now look forward to continued work with our partners to advance combination candidates into and through the clinic, with the goal of expanding treatment options for hard-to-treat cancers."
The study was designed to analyze the potential synergistic effects of combining DPX-based immunotherapies with bavituximab, Peregrine's investigational chimeric monoclonal antibody that targets PS.
This data follows ImmunoVaccine's 2016 AACR poster, which highlighted the potential for DPX-based cancer vaccines to improve tumor responses to checkpoint inhibitors. In February, the Company announced an investigator-sponsored Phase 2 clinical trial evaluating the use of the currently marketed anti-PD-1 drug, pembrolizumab when combined with ImmunoVaccine's lead immuno-oncology candidate, DPX-Survivac, and metronomic cyclophosphamide.
About DepoVax(TM)
DepoVax(TM) is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax(TM) platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability. Fully synthetic, off-the-shelf DepoVax(TM)-based vaccines are also relatively easy to manufacture, store, and administer. These characteristics enable ImmunoVaccine to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.
About ImmunoVaccine
ImmunoVaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. ImmunoVaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax(TM), the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. ImmunoVaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. An investigator-sponsored Phase 2 study is currently assessing the safety and efficacy of DPX-Survivac combined with an approved anti-PD-1 drug in advanced ovarian cancer. The Company is also exploring additional applications of DepoVax(TM), including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. ImmunoVaccine also has ongoing clinical projects to assess the potential of DepoVax(TM) to address malaria and the Zika virus. Connect at www.imvaccine.com.
We seek Safe Harbor.
Copyright (c) 2017 Canjex Publishing Ltd.
nNRA3m7mcb
• 05-Apr-2017 13:06:47 - IMMUNOVACCINE INC PRESENTS PRECLINICAL RESEARCH AT AACR 2017 ON ABILITY OF NOVEL MONOCLONAL ANTIBODIES TO BOOST EFFICACY OF DEPOVAX(TM)-BASED CANCER IMMUNOTHERAPY
• 05-Apr-2017 13:08:37 - IMMUNOVACCINE-DATA DEMONSTRATED PHOSPHATIDYLSERINE TARGETING ANTIBODIES CAN ENHANCE ANTI-CANCER ACTIVITY OF DEPOVAX-BASED THERAPEUTIC VACCINE PLATFORM
• 05-Apr-2017 13:08:43 - IMMUNOVACCINE INC - DATA SUGGESTS THAT ANTIBODY TARGETING PS CAN INCREASE ANTI-TUMOR IMMUNE RESPONSE INDUCED BY A DEPOVAX-BASED CANCER IMMUNOTHERAPY
BRIEF-Immunovaccine presents preclinical research on novel monoclonal antibodies - Reuters News
05-Apr-2017 13:21:01
April 5 (Reuters) - Immunovaccine Inc IMV.TO-
• Immunovaccine Inc presents preclinical research at aacr 2017 on ability of novel monoclonal antibodies to boost efficacy of depovax(tm)-based cancer immunotherapy
• Immunovaccine-Data demonstrated phosphatidylserine targeting antibodies can enhance anti-cancer activity of depovax-based therapeutic vaccine platform
• Immunovaccine Inc - data suggests that antibody targeting ps can increase anti-tumor immune response induced by a depovax-based cancer immunotherapy
Source text for Eikon: (Full Story)
Further company coverage: IMV.TO
Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax(TM)-based Cancer Immunotherapy - Market Wire
05-Apr-2017 13:05:00
Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax(TM)-based Cancer Immunotherapy
Study Part of Ongoing Effort to Identify Novel Combinations of DepoVax(TM)-based Immuno-oncology Candidates to Improve the Responses of Other Novel Immunotherapy Agents
HALIFAX, NOVA SCOTIA--(Marketwired - April 5, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that new preclinical data presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting demonstrated that phosphatidylserine (PS) targeting antibodies can enhance the anti-cancer activity of its DepoVax™-based therapeutic vaccine platform.
In the study, researchers combined a Peregrine Pharmaceuticals' PS-targeting antibody compound (mch1N11) with a DepoVax™-based HPV16 peptide vaccine and metronomic cyclophosphamide (mCPA). This combined immunotherapy prolonged survival in C3 mouse models as compared to mice receiving an isotope control in combination with DepoVax™/mCPA. Additional analysis also demonstrated an increase in T cells in the tumor following treatment. Taken together, researchers believe that the data suggests that the antibody targeting PS can increase the anti-tumor immune response induced by a DepoVax™-based cancer immunotherapy.
"This study is another step in our exploration of combining DepoVax™-based cancer vaccines and other promising immuno-modulatory compounds," said Marianne Stanford, PhD Vice President, Research for Immunovaccine. (https://www.imvaccine.com/team_management.php... process of generating supportive preclinical data to guide a potential clinical path forward has been effective in identifying these novel combinations in the past. We now look forward to continued work with our partners to advance combination candidates into and through the clinic, with the goal of expanding treatment options for hard-to-treat cancers."
The study was designed to analyze the potential synergistic effects of combining DPX-based immunotherapies with bavituximab, Peregrine's investigational chimeric monoclonal antibody that targets PS.
This data follows Immunovaccine's 2016 AACR poster, which highlighted the potential for DPX-based cancer vaccines to improve tumor responses to checkpoint inhibitors.
(https://www.imvaccine.com/releases.php...) In February, the Company announced an investigator-sponsored Phase 2 clinical trial evaluating the use of the currently marketed anti-PD-1 drug, pembrolizumab when combined with Immunovaccine's lead immuno-oncology candidate, DPX-Survivac, and metronomic cyclophosphamide.
About DepoVax™
DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax™ platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability. Fully synthetic, off-the-shelf DepoVax™-based vaccines are also relatively easy to manufacture, store, and administer. These characteristics enable Immunovaccine to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. An investigator-sponsored Phase 2 study is currently assessing the safety and efficacy of DPX-Survivac combined with an approved anti-PD-1 drug in advanced ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
MEDIA
Mike Beyer
Sam Brown Inc.
(312) 961-2502
mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbe
Chief Financial Officer
(902) 492-1819
info@imvaccine.com
Patti Bank
Managing Director
Westwicke Partners
O: (415) 513-1284 / T: (415) 515-4572 patti.bank@westwicke.com
PM .641 vol. 200
PM .64 vol 50000